174 related articles for article (PubMed ID: 36592144)
41. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
[TBL] [Abstract][Full Text] [Related]
42. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
[TBL] [Abstract][Full Text] [Related]
43. Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis.
Gono T; Kuwana M
Expert Rev Clin Immunol; 2020 Jan; 16(1):79-89. PubMed ID: 31779485
[No Abstract] [Full Text] [Related]
44. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
[TBL] [Abstract][Full Text] [Related]
45. Amyopathic and anti-TIF1 gamma-positive dermatomyositis: analysis of a monocentric cohort and proposal to update diagnostic criteria.
Didona D; Juratli HA; Scarsella L; Keber U; Eming R; Hertl M
Eur J Dermatol; 2020 Jun; 30(3):279-288. PubMed ID: 32666928
[TBL] [Abstract][Full Text] [Related]
46. A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor.
Varedi D; Frigerio A; Scaife C; Hull C
Dermatol Online J; 2019 Mar; 25(3):. PubMed ID: 30982303
[TBL] [Abstract][Full Text] [Related]
47. Recent advances in dermatomyositis-specific autoantibodies.
Fujimoto M; Watanabe R; Ishitsuka Y; Okiyama N
Curr Opin Rheumatol; 2016 Nov; 28(6):636-44. PubMed ID: 27533321
[TBL] [Abstract][Full Text] [Related]
48. Paraneoplastic anti-TIF1-gamma-positive dermatomyositis as expression of cervical squamous cell carcinoma recurrence.
van Erp MAJM; Slaats FMA; Emmen JMA; van Hamont D
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38262717
[TBL] [Abstract][Full Text] [Related]
49. Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis.
Parkes JE; Rothwell S; Oldroyd A; Chinoy H; Lamb JA;
Arthritis Res Ther; 2018 Jun; 20(1):117. PubMed ID: 29884237
[TBL] [Abstract][Full Text] [Related]
50. The Prevalence of Individual Histopathologic Features Varies according to Autoantibody Status in Muscle Biopsies from Patients with Dermatomyositis.
Pinal-Fernandez I; Casciola-Rosen LA; Christopher-Stine L; Corse AM; Mammen AL
J Rheumatol; 2015 Aug; 42(8):1448-54. PubMed ID: 26443871
[TBL] [Abstract][Full Text] [Related]
51. Case report of anti-transcription intermediary factor-1-γ/α antibody-positive dermatomyositis associated with gastric cancer and immunoglobulin G4-positive pulmonary inflammatory pseudotumor.
Ito K; Imafuku S; Hamaguchi Y; Fujimoto M; Nakayama J
J Dermatol; 2013 Jul; 40(7):567-9. PubMed ID: 23663102
[TBL] [Abstract][Full Text] [Related]
52. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.
Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
Rheumatology (Oxford); 2014 Mar; 53(3):433-7. PubMed ID: 24255164
[TBL] [Abstract][Full Text] [Related]
53. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report.
Kishi T; Tani Y; Okiyama N; Mizuochi K; Ichimura Y; Harigai M; Nagata S; Miyamae T
Pediatr Rheumatol Online J; 2021 Mar; 19(1):34. PubMed ID: 33740993
[TBL] [Abstract][Full Text] [Related]
54. [Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome].
Xing XY; Zhang JX; Zhu FY; Wang YF; Zhou XY; Li YH
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1214-1218. PubMed ID: 36533358
[TBL] [Abstract][Full Text] [Related]
55. Palmar erythema and palmar papules as predictors for dermatomyositis-related acute/subacute interstitial lung disease: a retrospective study.
Lu J; Liu C; Zhou X; Tang J; Liu S; Tang M; Li M; Zhu L
Rheumatology (Oxford); 2021 Dec; 61(1):413-421. PubMed ID: 33629112
[TBL] [Abstract][Full Text] [Related]
56. [Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies: an atypical case].
Girard C; Vincent T; Bessis D
Ann Dermatol Venereol; 2013 Oct; 140(10):628-34. PubMed ID: 24090894
[TBL] [Abstract][Full Text] [Related]
57. Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site.
Hori H; Ozeki Y; Kobashigawa T; Futsuhara K; Tanaka A; Watanabe E; Yabe H; Yago T; Fukuchi T; Sugawara H; Kotake S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):62-68. PubMed ID: 33269651
[TBL] [Abstract][Full Text] [Related]
58. Periorbital edema as the presenting sign of dermatomyositis.
Hall VC; Keeling JH; Davis MD
Int J Dermatol; 2003 Jun; 42(6):466-7. PubMed ID: 12786876
[TBL] [Abstract][Full Text] [Related]
59. Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features.
Troyanov Y; Targoff IN; Payette MP; Raynauld JP; Chartier S; Goulet JR; Bourré-Tessier J; Rich E; Grodzicky T; Fritzler MJ; Joyal F; Koenig M; Senécal JL
Medicine (Baltimore); 2014 Nov; 93(24):318-332. PubMed ID: 25500701
[TBL] [Abstract][Full Text] [Related]
60. Clinical presentation and evaluation of dermatomyositis.
Marvi U; Chung L; Fiorentino DF
Indian J Dermatol; 2012 Sep; 57(5):375-81. PubMed ID: 23112358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
